Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Physiologic and molecular consequences of endothelial Bmpr2 mutation.

Majka S, Hagen M, Blackwell T, Harral J, Johnson JA, Gendron R, Paradis H, Crona D, Loyd JE, Nozik-Grayck E, Stenmark KR, West J.

Respir Res. 2011 Jun 22;12:84. doi: 10.1186/1465-9921-12-84.

2.

BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.

Orriols M, Gomez-Puerto MC, Ten Dijke P.

Cell Mol Life Sci. 2017 Aug;74(16):2979-2995. doi: 10.1007/s00018-017-2510-4. Epub 2017 Apr 26. Review. Erratum in: Cell Mol Life Sci. 2017 May 23;:.

3.

Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.

West J.

Adv Exp Med Biol. 2010;661:265-78. doi: 10.1007/978-1-60761-500-2_17. Review.

PMID:
20204736
4.

Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.

West J, Austin E, Fessel JP, Loyd J, Hamid R.

Drug Discov Today. 2014 Aug;19(8):1241-5. doi: 10.1016/j.drudis.2014.04.015. Epub 2014 May 2. Review.

5.

Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension.

Morrell NW.

Adv Exp Med Biol. 2010;661:251-64. doi: 10.1007/978-1-60761-500-2_16. Review.

PMID:
20204735
6.

Genetics and the molecular pathogenesis of pulmonary arterial hypertension.

Liu D, Morrell NW.

Curr Hypertens Rep. 2013 Dec;15(6):632-7. Review.

PMID:
24078385
7.

From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.

Paulin R, Courboulin A, Barrier M, Bonnet S.

J Mol Med (Berl). 2011 Nov;89(11):1089-101. doi: 10.1007/s00109-011-0788-5. Epub 2011 Jul 15. Review.

PMID:
21761156
8.

Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.

Machado RD, Southgate L, Eichstaedt CA, Aldred MA, Austin ED, Best DH, Chung WK, Benjamin N, Elliott CG, Eyries M, Fischer C, Gräf S, Hinderhofer K, Humbert M, Keiles SB, Loyd JE, Morrell NW, Newman JH, Soubrier F, Trembath RC, Viales RR, Grünig E.

Hum Mutat. 2015 Dec;36(12):1113-27. doi: 10.1002/humu.22904. Epub 2015 Oct 12. Review.

9.

Mechanisms of disease: pulmonary arterial hypertension.

Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F.

Nat Rev Cardiol. 2011 Jun 21;8(8):443-55. doi: 10.1038/nrcardio.2011.87. Review.

PMID:
21691314
10.

Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.

Guignabert C, Bailly S, Humbert M.

Expert Opin Ther Targets. 2017 Feb;21(2):181-190. doi: 10.1080/14728222.2017.1275567. Epub 2016 Dec 28. Review.

PMID:
28001443
11.

BMPR2 spruces up the endothelium in pulmonary hypertension.

Xiong J.

Protein Cell. 2015 Oct;6(10):703-8. doi: 10.1007/s13238-015-0208-7. Review. No abstract available.

12.

Pulmonary arterial hypertension: the clinical syndrome.

Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT.

Circ Res. 2014 Jun 20;115(1):115-30. doi: 10.1161/CIRCRESAHA.115.301146. Review.

13.

The serotonin hypothesis of pulmonary hypertension revisited.

Maclean MR, Dempsie Y.

Adv Exp Med Biol. 2010;661:309-22. doi: 10.1007/978-1-60761-500-2_20. Review.

PMID:
20204739
14.

A systematic review of genetic mutations in pulmonary arterial hypertension.

Garcia-Rivas G, Jerjes-Sánchez C, Rodriguez D, Garcia-Pelaez J, Trevino V.

BMC Med Genet. 2017 Aug 2;18(1):82. doi: 10.1186/s12881-017-0440-5. Review.

15.

Cellular and molecular basis of pulmonary arterial hypertension.

Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S20-31. doi: 10.1016/j.jacc.2009.04.018. Review.

16.

Reconciling paradigms of abnormal pulmonary blood flow and quasi-malignant cellular alterations in pulmonary arterial hypertension.

Happé CM, Szulcek R, Voelkel NF, Bogaard HJ.

Vascul Pharmacol. 2016 Aug;83:17-25. doi: 10.1016/j.vph.2016.01.004. Epub 2016 Jan 22. Review.

PMID:
26804008
17.

Molecular pathogenesis and current pathology of pulmonary hypertension.

de Jesus Perez VA.

Heart Fail Rev. 2016 May;21(3):239-57. doi: 10.1007/s10741-015-9519-2. Review.

PMID:
26694808
18.

Id proteins in the vasculature: from molecular biology to cardiopulmonary medicine.

Yang J, Li X, Morrell NW.

Cardiovasc Res. 2014 Dec 1;104(3):388-98. doi: 10.1093/cvr/cvu215. Epub 2014 Oct 1. Review.

PMID:
25274246
19.

Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series).

Awad KS, West JD, de Jesus Perez V, MacLean M.

Pulm Circ. 2016 Sep;6(3):285-94. doi: 10.1086/688034. Review.

Supplemental Content

Support Center